CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
about
CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.Genetic alterations of human brain tumors as molecular prognostic factors.CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis.Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China.EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.Molecular markers of prognosis in astrocytic tumors.Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas.
P2860
Q30353881-D0F7CC4E-6076-4FFE-90AE-7F7F23A4D582Q35117832-A4F7C0B3-3FBB-4C1D-9185-79A43D8FC174Q35418206-61B0C397-8E45-46A9-AA18-7708B55384ADQ36118431-E8B914AD-DD63-4A5A-B0F3-D5E7503A45F0Q38459857-D398CC95-97FD-4A76-A7BD-E439B7307555Q44768519-01001A7F-9A3C-44BF-95D1-D62CCA5FAC87Q47193646-13052C01-66AB-4B8E-BBED-16BC228C13E3Q48117546-C48DB68D-EEE8-4E6E-B84C-DB06759F188DQ48215789-FD9A61B1-FE0D-4EDF-BAD5-A5F84231192BQ48263988-A262EAF8-D7AD-455F-B850-32DCC911F7E1Q48514271-95A27F07-13BF-47CA-BBA2-8522EF28745CQ54123926-EFF638FA-8F8F-4F20-BBFE-77565B6C20E3Q55474994-F3633EB1-0A5C-4EF3-B079-8E971C5A036E
P2860
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@en
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@nl
type
label
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@en
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@nl
prefLabel
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@en
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@nl
P2093
P356
P1476
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
@en
P2093
H Haapasalo
H Miettinen
L Paljärvi
P Sallinen
P2888
P304
P356
10.1023/A:1006185220369
P577
1999-02-01T00:00:00Z
P6179
1042955795